Investigational drug · Phase 2
BT7480
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "BT7480"
First trial start
2021
Nov 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BT7480", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BT7480" as an intervention, largest first.
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 ExpressionActive, not recruiting
BicycleTx LimitedIndustry
NCT05163041 · 200 participants (planned) · Start Nov 2, 2021 · Primary completion Aug 2026
Drug: BT7480; Nivolumab · For: Advanced Solid Tumor
Sites: Iowa City, Iowa; New York, New York; Cleveland, Ohio · 9 sites in all
- Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational ProductNot yet recruiting
BicycleTx LimitedIndustry
NCT07681674 · 16 participants (planned) · Start Aug 1, 2026 · Primary completion May 30, 2030
Drug: Zelenectide pevedotin; BT7480 and 1 more · For: Advanced Solid Tumors
Newest research
PubMed records naming it or its code names, newest first.
- Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology.
Upadhyaya P, Kristensson J, Lahdenranta J, et al. · J Med Chem 2022
- BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonistࡊ (Bicycle TICAࡊ) induces tumor localized CD137 agonism.
Hurov K, Lahdenranta J, Upadhyaya P, et al. · J Immunother Cancer 2021
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.